{"entity": "publication", "iuid": "a5ce651b3e474e7a9e437ce518f92a86", "timestamp": "2026-08-22T07:47:54.949Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a5ce651b3e474e7a9e437ce518f92a86.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a5ce651b3e474e7a9e437ce518f92a86"}}, "title": "Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.", "authors": [{"family": "Antimycobacterial Susceptibility Testing Group", "given": "", "initials": ""}], "type": "editorial", "published": "2022-04-00", "journal": {"title": "Eur. Respir. J.", "issn": "1399-3003", "volume": "59", "issue": "4", "issn-l": "0903-1936"}, "abstract": "Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6", "doi": "10.1183/13993003.00166-2022", "pmid": "35422426", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9059840"}, {"db": "pii", "key": "59/4/2200166"}], "notes": [], "created": "2026-08-21T12:33:26.696Z", "modified": "2026-08-21T12:33:26.722Z"}